WE CONTINUE TO BE AMAZED

HFS has overseen continuous research and results from its product kfibre and it continues to amaze, in all human trials where pathology is performed systemic inflammation measured by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) showed a drop in all subjects with the majority coming down to what is considered a normal level. (GGT)?gamma-glutamyl transferase is used as one of the measurement's to monitor your liver's health and if it remains constantly above what is considered the norm you are considered to have or be developing NAFLD. Recent case studies of >100 cases of Non Alcoholic Fatty Liver have shown that Kfibre with a matched probiotic and with some dietary changes and 3 hours of a healthy activity per week have the ability in both Woman and Men to change there GGT from high to normal within six weeks in all cases. HFS in August of 2022 registered a provisional Patent on Kfibre as a synergistic product with Probiotic/s in the treatment of Non Alcoholic Fatty Liver, Application # 2022902157